Emil D. Kakkis, President & CEO at Ultragenyx Pharmaceutical Inc. (RARE), sold 33,550 shares at $50.61 ($1.7M) on 2016-07-15, disclosed to the SEC on 2016-07-19.
Open-market sale of $1.7M RARE by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.61 | 13,550 | $686K | 40.3% |
| 2 | $50.61 | 13,550 | $686K | 40.3% |
| 3 | $51.34 | 6,450 | $331K | 19.4% |
| Total | $50.75 avg | 33,550 | $1.7M | 100% |
| Filing → |
| RARE | SELL | 2024-12-31 | $990K | — | Filing → |
| RARE | SELL | 2024-12-11 | $414K | — | Filing → |
| RARE | SELL | 2024-09-05 | $1.1M | — | Filing → |